目的 探讨杞黄降糖胶囊联合利拉鲁肽注射液治疗血糖控制不佳的2型糖尿病的临床疗效。方法 选取新乡市中心医院2021年11月至2022年5月收治的85例2型糖尿病患者。采用随机数字表法将85例2型糖尿病患者分为对照组（42例）和治疗组（43例）。对照组皮下注射利拉鲁肽注射液，起始0.6 mg/次，1次/d，１周后无不良反应则加量至1.2 mg/次。在对照组的基础上，治疗组口服杞黄降糖胶囊，6粒/次，3次/d。两组患者均治疗12周。观察两组的临床疗效，比较两组生活质量、血糖指标和胰岛素相关指标。结果 治疗后，对照组的总有效率为73.81%，治疗组的总有效率为93.02%，治疗组的总有效率高于对照组（P＜0.05）。治疗后，两组的生存质量量表（DMQLS）各维度评分均下降（P＜0.05），且治疗组DMQLS各维度评分均低于对照组（P＜0.05）。治疗后，两组空腹血糖（FBG）、餐后2 h血糖（2 h PG）、糖化血红蛋白（HbAlc）均下降（P＜0.05），且治疗组FBG、2 h PG、HbAlc均低于对照组（P＜0.05）。治疗后，两组胰岛素（FINS）、稳态模型胰岛β细胞分泌指数（HOMA-β）、稳态模型胰岛素抵抗指数（HOMA-IR）均升高（P＜0.05），且治疗组FINS、HOMA-β、HOMA-IR均高于对照组（P＜0.05）。结论 杞黄降糖胶囊联合利拉鲁肽注射液治疗血糖控制不佳的2型糖尿病可促进患者生活质量提升，有效控制血糖，改善胰岛素水平。

Objective To investigate the clinical efficacy of Qihuang Jiangtang Capsules combined with Liraglutide Injection in treatment of type 2 diabetes mellitus with poor glycemic control. Methods Patients (85 cases) with type 2 diabetes mellitus with poor glycemic control in Xinxiang Central Hospital from November 2021 to December 2022 were divided into the control group (42 cases) and the treatment group (43 cases) according to random number tablet method. Patients in the control group were sc administered with Liraglutide Injection, starting at 0.6 mg/time, once daily, if there were no adverse reactions after one week, the dosage was increased to 1.2 mg/time. Patients in the treatment group were po administered with Qihuang Jiangtang Capsules on the basis of the control group, 6 grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacies were evaluated, and the Quality of life, blood glucose indicators, and insulin related indicators in two groups were compared. Results After treatment, the total effective rate of the control group was 73.81%, while the total effective rate of the treatment group was 93.02%. The clinical total effective rate of the treatment group was higher than that of the control group (P＜0.05). After treatment, the scores of all dimensions of DMQLS in two groups decreased (P＜ 0.05), and the scores of all dimensions of DMQLS in the treatment group were lower than those in the control group (P＜0.05). After treatment, FBG, 2 h PG, and HbAlc in two groups were decreased (P＜0.05), and FBG, 2 h PG, and HbAlc in the treatment group were lower than those in the control group (P＜0.05). After treatment, FINS, HOMA-β, and HOMA-IR in two groups increased (P＜0.05), and FINS, HOMA-β, and HOMA-IR in the treatment group were higher than those in the control group (P＜0.05). Conclusion Qihuang Jiangtang Capsules combined with Liraglutide Injection in treatment of type 2 diabetes mellitus with poor glycemic control, which can improve the quality of life of patients, effectively control blood sugar and improve insulin levels.

R977

河南省医学科技攻关计划项目（LHGJ20191331）；新乡市神经重大疾病诊疗与转化重点实验室项目